Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.
Kawashima N, Akashi A, Nagata Y, Kihara R, Ishikawa Y, Asou N, Ohtake S, Miyawaki S, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kitamura K, Sakaida E, Takeshita A, Suzushima H, Naoe T, Matsumura I, Miyazaki Y, Ogawa S, Kiyoi H; Japan Adult Leukemia Study Group (JALSG). Kawashima N, et al. Among authors: ito y. Ann Hematol. 2019 Jan;98(1):83-91. doi: 10.1007/s00277-018-3492-5. Epub 2018 Sep 24. Ann Hematol. 2019. PMID: 30251205 Clinical Trial.
Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia.
Kuwatsuka Y, Tomizawa D, Kihara R, Nagata Y, Shiba N, Iijima-Yamashita Y, Shimada A, Deguchi T, Miyachi H, Tawa A, Taga T, Kinoshita A, Nakayama H, Kiyokawa N, Saito AM, Koh K, Goto H, Kosaka Y, Asou N, Ohtake S, Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kobayashi S, Kitamura K, Sakaida E, Ogawa S, Naoe T, Hayashi Y, Horibe K, Manabe A, Mizutani S, Adachi S, Kiyoi H. Kuwatsuka Y, et al. Among authors: ito y. Int J Hematol. 2018 Feb;107(2):201-210. doi: 10.1007/s12185-017-2340-z. Epub 2017 Oct 12. Int J Hematol. 2018. PMID: 29027108
Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study.
Harada Y, Nagata Y, Kihara R, Ishikawa Y, Asou N, Ohtake S, Miyawaki S, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kobayashi S, Kitamura K, Sakaida E, Onizuka M, Takeshita A, Ishida F, Suzushima H, Ishizawa K, Naoe T, Matsumura I, Miyazaki Y, Ogawa S, Kiyoi H; Japan Adult Leukemia Study Group JALSG. Harada Y, et al. Among authors: ito y. Leuk Res. 2018 Mar;66:20-27. doi: 10.1016/j.leukres.2018.01.008. Epub 2018 Jan 17. Leuk Res. 2018. PMID: 29360622 Clinical Trial.
Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.
Hatta Y, Mizuta S, Matsuo K, Ohtake S, Iwanaga M, Sugiura I, Doki N, Kanamori H, Ueda Y, Yoshida C, Dobashi N, Maeda T, Yujiri T, Monma F, Ito Y, Hayakawa F, Takeuchi J, Kiyoi H, Miyazaki Y, Naoe T. Hatta Y, et al. Among authors: ito y. Ann Hematol. 2018 Sep;97(9):1535-1545. doi: 10.1007/s00277-018-3323-8. Epub 2018 Apr 24. Ann Hematol. 2018. PMID: 29694642 Free PMC article.
Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study.
Ito Y, Wakita A, Takada S, Mihara M, Gotoh M, Ohyashiki K, Ohtake S, Miyawaki S, Ohnishi K, Naoe T. Ito Y, et al. Int J Hematol. 2012 Oct;96(4):485-91. doi: 10.1007/s12185-012-1165-z. Epub 2012 Sep 6. Int J Hematol. 2012. PMID: 22956429 Clinical Trial.
A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemia.
Iida H, Imada K, Ueda Y, Kubo K, Yokota A, Ito Y, Kiguchi T, Hata T, Nawa Y, Ikezoe T, Uchida T, Morita Y, Kawashima I, Chiba M, Morimoto K, Hirooka S, Miyazaki Y, Ohno R, Naoe T; Study Group. Iida H, et al. Among authors: ito y. Int J Hematol. 2022 May;115(5):694-703. doi: 10.1007/s12185-022-03307-x. Epub 2022 Feb 24. Int J Hematol. 2022. PMID: 35211840 Clinical Trial.
Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial.
Miyazaki Y, Kiguchi T, Sato S, Usuki K, Ishiyama K, Ito Y, Suzuki T, Taguchi J, Chiba S, Dobashi N, Tomita A, Harada H, Handa H, Horiike S, Maeda T, Matsuda M, Ichikawa M, Hata T, Honda S, Iyama S, Suzushima H, Moriuchi Y, Kurokawa T, Yokota K, Ohtake S, Yamauchi T, Matsumura I, Kiyoi H, Naoe T; Japan Adult Leukemia Study Group. Miyazaki Y, et al. Among authors: ito y. Int J Hematol. 2022 Aug;116(2):228-238. doi: 10.1007/s12185-022-03347-3. Epub 2022 May 4. Int J Hematol. 2022. PMID: 35508695 Clinical Trial.
Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.
Ueda Y, Mizutani C, Nannya Y, Kurokawa M, Kobayashi S, Takeuchi J, Tamura H, Ogata K, Dan K, Shibayama H, Kanakura Y, Niimi K, Sasaki K, Watanabe M, Emi N, Teramura M, Motoji T, Kida M, Usuki K, Takada S, Sakura T, Ito Y, Ohyashiki K, Ogawa H, Suzuki T, Ozawa K, Imai K, Kasai M, Hata T, Miyazaki Y, Morita Y, Kanamaru A, Matsuda A, Tohyama K, Koga D, Tamaki H, Mitani K, Naoe T, Sugiyama H, Takaku F. Ueda Y, et al. Among authors: ito y. Leuk Lymphoma. 2013 Jul;54(7):1450-8. doi: 10.3109/10428194.2012.745074. Epub 2012 Nov 26. Leuk Lymphoma. 2013. PMID: 23110324
12,184 results
You have reached the last available page of results. Please see the User Guide for more information.